News Sentiment

ALDX sentiment intelligence

Aldeyra The news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 41 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.07 Week of 10 Jul 2026
Weighted tone 41/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-8.8% over one week, +17.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Aldeyra Therapeutics (NASDAQ: ALDX) advances FDA dialogue on reproxalap NDA

Market Reaction

Price moving ahead of tone

70/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -8.8% Price reacting lower
Trend fit Trend inactive 17.6% over four weeks
Fair value -51.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 3
Neutral 39
Negative 17

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Market source 10
ACCESS Newswire 6
simplywall.st 6
Stocktwits 4
www.marketscreener.com 3
Stock Titan 2
MarketBeat 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 13
Regulatory and legal 8
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Stock Titan Direct company coverage

Aldeyra Therapeutics (NASDAQ: ALDX) advances FDA dialogue on reproxalap NDA

Aldeyra Therapeutics (NASDAQ: ALDX) reported ongoing regulatory discussions with the FDA concerning the New Drug Application (NDA) for reproxalap, intended for dry eye disease treatment. The company received minutes from a Type A meeting on July 14, 2026, and is now seeking clari

Tone
Neutral 50/100
Event
Regulatory and legal
Published
15 Jul 2026 21:13
Source
Stock Titan
TradingView Direct company coverage

Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission

Aldeyra Therapeutics plans to request a Type D meeting with the FDA to discuss a potential New Drug Application (NDA) resubmission for reproxalap, a treatment for dry eye disease. This decision follows their request for clarification on FDA minutes from a June 10, 2026 Type A mee

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 21:13
Source
TradingView
MarketBeat Direct company coverage

Aldeyra Therapeutics (ALDX) Short Interest & Short Float | Updated Jul 2026

Aldeyra Therapeutics (ALDX) saw a significant decline in short interest during June 2026, with the total number of shares sold short decreasing by 17.34% to 5.68 million shares. This represents 10.67% of the public float and a short interest ratio of 2.5 days to cover. The change

Tone
Negative 40/100
Event
Market update
Published
11 Jul 2026 00:40
Source
MarketBeat
timothysykes.com Direct company coverage

Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Aldeyra Therapeutics Inc. (ALDX) stock. It includes current stock price, financial details, and analyst ratings, noting that there are no current analyst ratings or earnings information available for ALDX. The page also features a dis

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 23:11
Source
timothysykes.com
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (ALDX) securities. The investigation focuses on whether Aldeyra and its officers engaged in corporate wrongdoing, particularly for investors who bought share

Tone
Negative 19/100
Event
Regulatory and legal
Published
09 Jul 2026 11:00
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aldeyra Therapeutics, Inc. (ALDX) for alleged corporate wrongdoing. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to connect and assist

Tone
Negative 32/100
Event
Market update
Published
07 Jul 2026 11:00
Source
ACCESS Newswire
Stocktwits Direct company coverage

Why Did ALDX Stock Tank 70% Today?

Aldeyra Therapeutics Inc. (ALDX) stock plummeted almost 70% after the U.S. FDA rejected its application for a dry eye drug, citing insufficient and inconsistent clinical data. The FDA noted a "lack of substantial evidence" and raised concerns about the reliability of positive fin

Tone
Negative 8/100
Event
Market update
Published
06 Jul 2026 10:39
Source
Stocktwits
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) concerning alleged corporate wrongdoing. The firm encourages shareholders who purchased Aldeyra securities before November 3, 2023, and still h

Tone
Negative 29/100
Event
Regulatory and legal
Published
05 Jul 2026 11:00
Source
ACCESS Newswire
Simply Wall Street Direct company coverage

Spotlight On Aldeyra Therapeutics And 2 Other Prominent Penny Stocks

This article highlights three prominent penny stocks—Aldeyra Therapeutics (ALDX), Anavex Life Sciences (AVXL), and Waterdrop (WDH)—that exhibit strong balance sheets and potential for significant returns. Despite challenges like index exclusions for Aldeyra and Anavex, these comp

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 21:40
Source
Simply Wall Street
TradingView Direct company coverage

Aldeyra Therapeutics, Inc. Actuals & Estimates (TRADEGATE:137)

This article provides an overview of Aldeyra Therapeutics, Inc. (TRADEGATE:137) including its financial actuals and estimates. It covers analyst price targets, historical stock prices, upcoming earnings reports, and recent financial performance metrics like earnings per share and

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 00:09
Source
TradingView
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (ALDX) and its officers. The firm is encouraging Aldeyra shareholders who purchased securities before November 3, 2023, and continue to hold them, to

Tone
Negative 28/100
Event
Regulatory and legal
Published
02 Jul 2026 11:00
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aldeyra Therapeutics, Inc. (ALDX) concerning potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023,

Tone
Negative 9/100
Event
Regulatory and legal
Published
30 Jun 2026 20:09
Source
ACCESS Newswire
The National Law Review Direct company coverage

ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors who su

Tone
Negative 13/100
Event
Regulatory and legal
Published
30 Jun 2026 15:40
Source
The National Law Review
marketscreener.com Direct company coverage

Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Value Benchmark

Aldeyra Therapeutics, Inc. (ALDX) has been removed from the Russell 2000 Value Benchmark. This news follows a period of significant activity for the company, including recent appointments to its board, insider share purchases, and a decline in its stock value after the FDA declin

Tone
Negative 29/100
Event
Market update
Published
30 Jun 2026 11:07
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) dropped from Russell 2500 Growth Benchmark

Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) has been removed from the Russell 2500 Growth Benchmark as of June 29, 2026. This biotechnology company develops therapies for immune-mediated and metabolic diseases, with product candidates like reproxalap for dry eye disease. The news

Tone
Negative 18/100
Event
Market update
Published
29 Jun 2026 15:25
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell 3000E Growth Benchmark

Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) has been removed from the Russell 3000E Growth Benchmark. This news follows a period of significant stock performance fluctuation and comes after several announcements regarding board appointments, insider share purchases, and a recent F

Tone
Negative 20/100
Event
Market update
Published
29 Jun 2026 12:12
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Dynamic Index

Aldeyra Therapeutics, Inc. (ALDX) has been removed from the Russell 2000 Dynamic Index. This news comes amidst other recent updates for the biotechnology company, including executive appointments, insider share purchases, and a significant setback with the U.S. FDA declining appr

Tone
Negative 19/100
Event
Market update
Published
29 Jun 2026 05:28
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 3000 Index

Aldeyra Therapeutics, Inc. (NasdaqCM: ALDX) has been removed from the Russell 3000 Index. The biotechnology company, which focuses on immune-mediated and metabolic diseases, also recently announced the appointment of Darlene Deptula-Hicks to its Board of Directors and reported ea

Tone
Negative 18/100
Event
Market update
Published
29 Jun 2026 05:11
Source
www.marketscreener.com
TradingView Direct company coverage

137 Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Aldeyra Therapeutics, Inc. (137) based on analyst opinions. It includes financial data, past performance, and upcoming earnings information. The company's highest price on record was 13.61 EUR, and the lowest was 1.05 EUR, wit

Tone
Positive 60/100
Event
Analyst action
Published
28 Jun 2026 11:09
Source
TradingView
ACCESS Newswire Direct company coverage

Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (ALDX). The investigation focuses on whether the company and its officers engaged in corporate wrongdoing, specifically for investors who bought securities b

Tone
Negative 28/100
Event
Regulatory and legal
Published
28 Jun 2026 11:00
Source
ACCESS Newswire
TradingView Direct company coverage

ALDX Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Aldeyra Therapeutics, Inc. (ALDX) stock for 2027, based on analyst opinions. It includes current stock performance metrics, historical price data, financial insights, and upcoming earnings information. The content emphasizes t

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 06:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX

This article provides financial information for Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), specifically focusing on its "Price to book forward" metric. The content highlights the company's stock market presence on Nasdaq and offers a brief overview of available financial data.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 06:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of Aldeyra Therapeutics, Inc. – DUS:137

This page from TradingView provides financial information for Aldeyra Therapeutics, Inc. (DUS:137), specifically focusing on its "Price to book forward" metric. The content includes navigation to various financial tools, market data, and community features, but the primary articl

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 04:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Aldeyra Therapeutics, Inc. – DUS:137

This article provides the "Price to sales forward" value for Aldeyra Therapeutics, Inc. (DUS:137). It indicates the financial data is currently unavailable as the market is closed with no trades recorded. The content functions as a placeholder or an unpopulated financial data pag

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 19:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Aldeyra Therapeutics, Inc. – DUS:137

This article displays the forward enterprise value to revenue for Aldeyra Therapeutics, Inc. (DUS:137). It shows that the "Period Value" and related "Change" and "Change %" metrics are currently empty, indicating no available data at this time. The data is provided by TradingView

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 15:41
Source
TradingView
TradingView Direct company coverage

Aldeyra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc. (ALDX) stock is currently trading at 1.83 USD, experiencing a -5.26% decrease in the past 24 hours. Analysts predict a future price range of 2.00 USD to 13.00 USD. The company's market capitalization is 108.58M USD, and it will release its next earnings

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 14:41
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX

This page from TradingView displays the "Price to earnings forward" for Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). It appears to be a financial data point without further analysis or specific values provided directly on this snippet. The content is primarily a page title within t

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:41
Source
TradingView